In our study, patients in the high-risk group had primary gliomas, exhibited GBM histology, high-grade, advanced age, IDH wild type, 1p/19q non-codeletion, and MGMT promoter un-methylation (Figure 2C and Table 2). This evidence concerns the gene IDH2 and glioblastoma.